No, the P3 trials are separate. one for treatment naive wh/ is more advanced in clinical trials and one for treatment refractory wh/ has been associated w/ higher or >200mg NM283 dosage.
The company would not delay the naive P3 trial for the sake of a refractory P3 trial.
The creation of a thousand forests is in one acorn.
Market Data 
Markets 
AI
